Serum T 50 predicts cardiovascular mortality in individuals with type 2 diabetes: A prospective cohort study.
Amarens van der VaartCoby EelderinkHarry van GoorJan-Luuk HillebrandsCharlotte A Te Velde-KeyzerStephan J L BakkerAndreas PaschPeter R van DijkGozewijn D LavermanMartin H de BorstPublished in: Journal of internal medicine (2024)
Serum T50 improves prediction of cardiovascular and all-cause mortality risk in individuals with T2D. Serum T50 may be useful for risk stratification and to guide therapeutic strategies aiming to reduce cardiovascular mortality in T2D.